C-reactive Protein Testing Market to Grow with a CAGR of 2.16% through 2028
Growing demand of Monitor the
effectiveness of treatment for inflammatory conditions or cardiovascular
disease are the major drivers for the Global C-reactive Protein Testing Market.
According
to TechSci Research report, “C-reactive Protein Testing Market –Global Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, the
Global C-reactive Protein Testing Market stood at USD1601.01 million in
2022 and is anticipated to project robust growth in the forecast period with a
CAGR of 2.16% through 2028. This can be ascribed to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
C-reactive Protein Testing are test is a blood test
that measures the level of C-reactive protein (CRP) in your blood. CRP is a
protein made by your liver. Normally, you have low levels of CRP in your blood.
Your liver releases more CRP into your bloodstream if you have inflammation in
your body. Significant growth in the healthcare industry across the globe
represents one of the key factors creating a positive outlook for the market.
Furthermore, the increasing demand for chronic disease management and patient
empowerment is also driving the market growth. C-reactive protein (CRP) testing
is used to measure the levels of C-reactive protein in a person's blood.
CRP is a protein produced by the liver in response
to inflammation, which is the body's natural response to injury, infection, or
various medical conditions that lead to the increasing demand for C-reactive
Protein Testing. According to a report published in February 2022 by Oberto, a
Russia-based drop shipping company, the fashion industry grew by 18.4 % in
2021, with sales figures for 2022 forecast at $473.42 billion. Therefore, the
increasing demand for CRP testing is in high demand for diagnosing and
monitoring various inflammatory conditions, including infections, autoimmune
disorders, and chronic inflammatory diseases.
Healthcare providers use CRP levels to assess
disease activity, guide treatment decisions, and monitor the response to
therapies. C-reactive protein (CRP) testing is used in various clinical and
medical contexts to assess inflammation levels in the body. CRP testing is used
as a biomarker to assess cardiovascular risk. Elevated CRP levels have been
associated with an increased risk of cardiovascular diseases, including heart
attacks and strokes. It is used in conjunction with other risk factors to
estimate an individual's risk of cardiovascular events. Moreover, leading
players operating in the industry are focusing on technological innovations to
offer a better customer experience. They are also engaging in partnerships and
collaborations to increase their brand presence.
Apart from this, After surgical procedures, CRP
testing helps monitor the body's response to surgical trauma and inflammation.
Elevated CRP levels post-surgery can indicate complications or a prolonged
inflammatory response. Moreover, Elevated CRP levels have been linked to
increased cardiovascular risk. As heart disease is a leading cause of morbidity
and mortality globally, CRP testing is widely used for cardiovascular risk
assessment and prevention strategies. This, CRP testing plays a crucial role in
preventive medicine by identifying individuals at risk for chronic diseases
such as cardiovascular diseases, diabetes, and certain cancers. This aligns
with the growing emphasis on early disease detection and intervention. There is
a growing emphasis on early detection Preventive healthcare focuses on
identifying health issues at an early stage, even before symptoms become
apparent. CRP testing serves as a valuable tool in this context by detecting
low-grade inflammation that might not be clinically evident yet.
Early detection of inflammation through CRP testing
enables timely intervention and management, potentially preventing the
progression of underlying diseases. These methods aim to identify diseases,
conditions, or health risks at the earliest possible stage, often before
noticeable symptoms or significant complications develop. Early detection plays
a critical role in improving patient outcomes, increasing treatment success
rates, and reducing the overall burden of disease. Additionally, Government
initiatives related to the global C-reactive protein (CRP) testing market can
vary by country and region. These initiatives often aim to promote public
health, improve disease management, enhance early detection, and support
research efforts. They also provide support in establishing health screening
programs that include CRP testing as part of routine check-ups or specific
health assessments.
These programs are designed to identify individuals
at risk of inflammatory or cardiovascular conditions and provide early
intervention. Governments often run public awareness campaigns to educate the
population about the importance of early detection and the role of CRP testing
in assessing inflammation and disease risk. These campaigns aim to encourage
individuals to seek preventive healthcare. Through strategic partnerships,
brands, manufacturers, and testing players can collaborate to implement
sustainable practices that effectively diagnose the cause of disease and start
early treatment. The CRP testing market generates revenue through the sale of
testing kits, reagents, and equipment to healthcare providers, laboratories,
and medical institutions. The increased demand for CRP testing products and
services contributes to healthcare sector revenues. Roche to acquire biopharma
firm Good therapeutics for USD 250 m.
Roche’s IL-2 drug business is focused on developing
conditionally active drugs based on innovative IL-2 drug technology that are
PD-1 regulated. In the context of the acquisition, Roche obtains the rights to
an IL-2 drug that is conditionally active and PD-1 regulated, which is called
the Good Therapeutic Programme. Roche also obtains the exclusive use of the
platform technology developed by Good Therapeutic for the development of IL-2
drug therapy that is PD-1 regulated and receptor agonist therapy.
However, Non-specificity of elevated CRP and Varied
Reference ranges are expected to slow down the growth of the market in the
coming years.
Browse
over XX market data Figures and spread through xx Pages and an in-depth TOC on
"Global C-reactive Protein Testing Market.”
The Global C-reactive Protein Testing Market
segmentation is based on Assay Type, Detection Range, disease Area, End-Use
Industry, By Company, and Region.
Some
of the major companies operating in the Global
C-reactive Protein Testing Market include:
- Thermo
Fisher Scientific, Inc.
- F.
Hoffmann-La Roche Ltd.
- Danaher
Corporation
- Quest
Diagnostics
- Siemens
Healthineers AG
- Abbott
laboratories Inc.
- Merck
KGaAA
- Zoetis
Inc.
- Ortho
Clinical Diagnostics
- Getein
Biotech, Inc.
Download
Free Sample Report
Customers can also request for 10% free
customization on this report.
“Certain regions, particularly North
America, are projected to exert significant demand for C-reactive Protein
Testing worldwide. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhancing their
C-reactive Protein Testing productivity each year, are expected to contribute
to a remarkable growth of the Global C-reactive Protein Testing Market in the
forecast period," said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based Global management consulting firm.
C-reactive
Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented By Assay Type (Immunoturbidimetric Assay, ELISA,
Chemiluminescence Immunoassay, Others), By Detection Range (hs-CRP,
Conventional CRP, cCRP), By Disease Area (Cardiovascular Diseases, Cancer,
Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus,
Others), By End-Use Industry (Clinics & Hospitals, Laboratories, Assisted
Living Healthcare Facilities, Home, Others), By Region, Competition
has evaluated the future growth potential of Global C-reactive Protein Testing
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global C-reactive Protein
Testing Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com